<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040742</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069401</org_study_id>
    <secondary_id>U10CA037420</secondary_id>
    <secondary_id>URCC U1902</secondary_id>
    <secondary_id>URCC-0114</secondary_id>
    <nct_id>NCT00040742</nct_id>
  </id_info>
  <brief_title>Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer</brief_title>
  <official_title>A Phase II/III Randomized, Controlled Clinical Trial Of Ginger (Zingiber Officinale) For Nausea Caused By Chemotherapy For Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary Morrow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Ginger may help reduce or prevent nausea. It is not yet known if antiemetic drugs
      are more effective with or without ginger in treating nausea caused by chemotherapy.

      PURPOSE: This randomized phase II/III trial is studying giving antiemetic drugs together with
      ginger to see how well they work compared to antiemetic drugs alone in treating nausea in
      patients who are receiving chemotherapy for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of 1 course of ginger vs placebo when administered in regimens
           containing a 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist antiemetic and
           dexamethasone (or the equivalent dose of IV methylprednisolone) in controlling
           chemotherapy-related nausea at course 2 of chemotherapy in patients with cancer.

        -  Compare the efficacy of 3 different doses of ginger in controlling chemotherapy-related
           nausea in these patients.

        -  Determine the adverse effects of ginger when given 3 days before chemotherapy
           administration in these patients.

        -  Determine the adverse effects of these antiemetic regimens during the 4 days after
           chemotherapy.

        -  Compare the chemotherapy-related anticipatory nausea in patients treated with these
           antiemetic regimens.

        -  Compare the quality of life during the 4 days after chemotherapy in patients treated
           with these antiemetic regimens.

        -  Compare the chemotherapy-related nausea at course 3 of chemotherapy in these patients
           after 2 courses of ginger vs placebo.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to participating center. Patients are randomized to 1 of 4 treatment
      arms. Day 1 of each course is defined as the day of chemotherapy administration.

        -  Placebo: Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy
           courses 2 and 3.

        -  0.5g Ginger: Patients receive oral low-dose ginger and oral placebo twice daily on days
           -3 to 3 of chemotherapy courses 2 and 3.

        -  1.0g Ginger: Patients receive oral intermediate-dose ginger and oral placebo twice daily
           on days -3 to 3 of chemotherapy courses 2 and 3.

        -  1.5g Ginger: Patients receive oral high-dose ginger twice daily on days -3 to 3 of
           chemotherapy courses 2 and 3.

      Patients in each arm also continue receiving their scheduled antiemetic regimen comprising a
      5-hydroxytryptamine type-3 (5-HT3) receptor antagonist (ondansetron, granisetron,
      tropisetron, and dolasetron mesylate) and dexamethasone (DM) (or the equivalent dose of IV
      methylprednisolone (MePRDL)) on day 1 of courses 2 and 3.

      Symptoms are assessed on day -3 to day 1 of courses 2 and 3 and on days 1-4 of courses 1-3.

      Quality of life is assessed on day 4 of courses 1-3.

      Nausea and vomiting are assessed 4 times daily on days 1-4 of courses 1-3.

      PROJECTED ACCRUAL: A total of 706 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline of Peak Acute Nausea</measure>
    <time_frame>3-4 days on study drug</time_frame>
    <description>Nausea evaluated on a 7-point semantic rating scale anchored by &quot;1&quot; = &quot;Not at all nauseated&quot; and by &quot;7&quot; = &quot;Extremely nauseated.&quot; Acute nausea calculated as the maximum of the Day 1 Evening and Night nausea ratings.
Change from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of peak acute nausea used as the outcome measure.
Negative values for this outcome are favorable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Nausea Severity</measure>
    <time_frame>3-4 days on study drug</time_frame>
    <description>Nausea evaluated on a 7-point semantic rating scale anchored by &quot;1&quot; = &quot;Not at all nauseated&quot; and by &quot;7&quot; = &quot;Extremely nauseated.&quot; Acute nausea calculated as the average of the Day 1 Evening and Night nausea ratings.
Change from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of average acute nausea used as the outcome measure.
Negative values for this outcome are favorable.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">745</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5g ginger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0g ginger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5g ginger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ginger</intervention_name>
    <description>Given orally</description>
    <arm_group_label>0.5g ginger</arm_group_label>
    <arm_group_label>1.0g ginger</arm_group_label>
    <arm_group_label>1.5g ginger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>0.5g ginger</arm_group_label>
    <arm_group_label>1.0g ginger</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of cancer and be scheduled to receive at least 3 courses of chemotherapy

               -  Scheduled to receive chemotherapy with no planned interruption by radiotherapy or
                  surgery

               -  Chemotherapy courses must be separated by at least 2 weeks from day 1 to day 1 of
                  next course

          -  Must have experienced nausea of any degree of severity after completion of the first
             study-related course of chemotherapy

          -  Received a prior 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist antiemetic
             (ondansetron, granisetron, tropisetron, or dolasetron mesylate) with dexamethasone
             (DM) given at any dose and by any route (or equivalent dose of IV methylprednisolone
             (MePRDL)) on day 1 of course 1 of chemotherapy

          -  Scheduled to receive a 5-HT3 receptor antagonist antiemetic with DM (or equivalent
             dose of IV MePRDL) on day 1 of courses 2 and 3 of chemotherapy

          -  No symptomatic brain metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Platelet count greater than 100,000/mm^3 at second course of chemotherapy

          -  No prior bleeding or blood coagulation disorder (e.g., thrombocytopenia or platelet
             dysfunction)

        Hepatic:

          -  No prior coagulation factor deficiency

        Renal:

          -  Not specified

        Cardiovascular:

          -  No prior vascular defect

        Other:

          -  Able to understand English

          -  No concurrent or impending bowel obstruction

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent interferon therapy

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 6 months since other prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No concurrent radiotherapy

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No concurrent warfarin or heparin for therapeutic anticoagulation

          -  Concurrent low-dose warfarin for maintenance of venous access allowed

          -  Concurrent rescue medications for control of symptoms caused by the cancer or its
             treatment allowed as clinically indicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie L. Ryan, PhD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MBCCOP - Gulf Coast</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-7323</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Hematology-Oncology Associates of Central New York</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - North Shore University Hospital</name>
      <address>
        <city>Manhassett</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southeast Cancer Control Consortium</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534-9479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbia River Oncology Program</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northwest</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405-0986</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Marshfield Clinic Research Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>July 10, 2014</results_first_submitted>
  <results_first_submitted_qc>February 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2015</results_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Gary Morrow</investigator_full_name>
    <investigator_title>Director, URCC CCOP Research Base</investigator_title>
  </responsible_party>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
placebo: Given orally</description>
        </group>
        <group group_id="P2">
          <title>0.5g Ginger</title>
          <description>Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="P3">
          <title>1.0g Ginger</title>
          <description>Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="P4">
          <title>1.5g Ginger</title>
          <description>Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="187"/>
                <participants group_id="P4" count="186">One subject found to be ineligible after randomization. No baseline data collected.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="141"/>
                <participants group_id="P4" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chemotoxicity</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incomplete Forms</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other medical</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
placebo: Given orally</description>
        </group>
        <group group_id="B2">
          <title>0.5g Ginger</title>
          <description>Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="B3">
          <title>1.0g Ginger</title>
          <description>Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="B4">
          <title>1.5g Ginger</title>
          <description>Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="141"/>
            <count group_id="B4" value="152"/>
            <count group_id="B5" value="576"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="10.62"/>
                    <measurement group_id="B2" value="54" spread="11.58"/>
                    <measurement group_id="B3" value="52" spread="10.69"/>
                    <measurement group_id="B4" value="52" spread="9.86"/>
                    <measurement group_id="B5" value="52.75" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="142"/>
                    <measurement group_id="B5" value="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="142"/>
                    <measurement group_id="B5" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>College Grad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H.S. Grad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some/No HS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous chemotherapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous radiation therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="144"/>
                    <measurement group_id="B5" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor site</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Alimentary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gynecologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline average nausea, Day1</title>
          <description>Average nausea evaluated using a 7-point semantic rating scale anchored by &quot;1&quot; = &quot; Not at all nauseated&quot; and by &quot;7&quot; = &quot;Extremely nauseated.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="1.6"/>
                    <measurement group_id="B2" value="2.6" spread="1.9"/>
                    <measurement group_id="B3" value="2.5" spread="1.8"/>
                    <measurement group_id="B4" value="2.4" spread="1.7"/>
                    <measurement group_id="B5" value="2.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline nausea at its worst</title>
          <description>Maximum nausea evaluated using a 7-point semantic rating scale anchored by &quot;1&quot; = &quot; Not at all nauseated&quot; and by &quot;7&quot; = &quot;Extremely nauseated.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="1.7"/>
                    <measurement group_id="B2" value="2.9" spread="2.1"/>
                    <measurement group_id="B3" value="2.8" spread="2.0"/>
                    <measurement group_id="B4" value="2.7" spread="2.0"/>
                    <measurement group_id="B5" value="2.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of life(FACT-G)</title>
          <description>Quality of life is evaluated using the Functional Assessment of Cancer Therapy-General (FACT-G), a 27-item compilation of questions divided into 4 primary domains: Physical Well-Being (PWB)[range 0 - 28], Social Well-Being (SWB)[range 0 - 28], Emotional Well-Being (EWB) [range 0 - 24], and Functional Well-Being (FWB) [range 0 - 28]. Total FACT-G score is a sum of the 4 primary domains [range 0 - 108]. The higher the score, the better.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="15.9"/>
                    <measurement group_id="B2" value="72" spread="15.0"/>
                    <measurement group_id="B3" value="71" spread="15.4"/>
                    <measurement group_id="B4" value="72" spread="16.0"/>
                    <measurement group_id="B5" value="72" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of Peak Acute Nausea</title>
        <description>Nausea evaluated on a 7-point semantic rating scale anchored by &quot;1&quot; = &quot;Not at all nauseated&quot; and by &quot;7&quot; = &quot;Extremely nauseated.&quot; Acute nausea calculated as the maximum of the Day 1 Evening and Night nausea ratings.
Change from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of peak acute nausea used as the outcome measure.
Negative values for this outcome are favorable.</description>
        <time_frame>3-4 days on study drug</time_frame>
        <population>Eligible patients 18 years of age or older, able to understand English, diagnosed with cancer, may have received more than one chemotherapy cycle and scheduled for at least three additional cycles; randomization stratified by CCOP site. A computer-generated random numbers table assigned patients to one of four treatment arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>0.5g Ginger</title>
            <description>Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>1.0g Ginger</title>
            <description>Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
          </group>
          <group group_id="O4">
            <title>1.5g Ginger</title>
            <description>Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Peak Acute Nausea</title>
          <description>Nausea evaluated on a 7-point semantic rating scale anchored by &quot;1&quot; = &quot;Not at all nauseated&quot; and by &quot;7&quot; = &quot;Extremely nauseated.&quot; Acute nausea calculated as the maximum of the Day 1 Evening and Night nausea ratings.
Change from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of peak acute nausea used as the outcome measure.
Negative values for this outcome are favorable.</description>
          <population>Eligible patients 18 years of age or older, able to understand English, diagnosed with cancer, may have received more than one chemotherapy cycle and scheduled for at least three additional cycles; randomization stratified by CCOP site. A computer-generated random numbers table assigned patients to one of four treatment arms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.85"/>
                    <measurement group_id="O2" value="-0.56" spread="1.83"/>
                    <measurement group_id="O3" value="-0.44" spread="1.79"/>
                    <measurement group_id="O4" value="-0.15" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Mean difference between 0.5g and placebo of change from baseline of Peak Acute Nausea = 0.
Ha: Mean difference between 0.5g and placebo of change from baseline of Peak Acute Nausea &gt; 0. (Two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.017</p_value>
            <p_value_desc>The p-value was adjusted using theTukey-Kramer method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model analyses and Type 3 tests of fixed effects using the Kenward-Roger degrees of freedom procedure were used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.566</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.145</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter (mean difference) is the difference in mean change from baseline (post-intervention - baseline) between groups (0.5 gm ginger - placebo). Negative values are favorable for the ginger group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: Mean difference between 1.0g and placebo of change from baseline of Peak Acute Nausea = 0.
Ha: Mean difference between 1.0g and placebo of change from baseline of Peak Acute Nausea &gt; 0. (Two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>The p-value was adjusted using theTukey-Kramer method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model analyses and Type 3 tests of fixed effects using the Kenward-Roger degrees of freedom procedure were used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.506</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.141</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter (mean difference) is the difference in mean change from baseline (post-intervention - baseline) between groups (1 gm ginger - placebo). Negative values are favorable for the ginger group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>H0: Mean difference between 1.5g and placebo of change from baseline of Peak Acute Nausea = 0.
Ha: Mean difference between 1.5g and placebo of change from baseline of Peak Acute Nausea &gt; 0. (Two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.431</p_value>
            <p_value_desc>The p-value was adjusted using theTukey-Kramer method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model analyses and Type 3 tests of fixed effects using the Kenward-Roger degrees of freedom procedure were used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.269</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter (mean difference) is the difference in mean change from baseline (post-intervention - baseline) between groups (1.5 gm ginger - placebo). Negative values are favorable for the ginger group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo vs. Any Ginger. H0: Mean difference between [(0.5g +1.0g +1.5g) / 3] and placebo of change from baseline of Peak Acute Nausea = 0.
Ha: Mean difference between [(0.5g +1.0g +1.5g) / 3] and placebo of change from baseline of Peak Acute Nausea &gt; 0. (Two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Parameter estimated using a contrast.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.470</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.160</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter (mean difference) is the difference in mean change from baseline (post-intervention - baseline) between groups (any ginger - placebo). Negative values are favorable for the ginger group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Nausea Severity</title>
        <description>Nausea evaluated on a 7-point semantic rating scale anchored by &quot;1&quot; = &quot;Not at all nauseated&quot; and by &quot;7&quot; = &quot;Extremely nauseated.&quot; Acute nausea calculated as the average of the Day 1 Evening and Night nausea ratings.
Change from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of average acute nausea used as the outcome measure.
Negative values for this outcome are favorable.</description>
        <time_frame>3-4 days on study drug</time_frame>
        <population>Eligible patients 18 years of age or older, able to understand English, diagnosed with cancer, may have received more than one chemotherapy cycle and scheduled for at least three additional cycles; randomization stratified by CCOP site. A computer-generated random numbers table assigned patients to one of four treatment arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>0.5g Ginger</title>
            <description>Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>1.0g Ginger</title>
            <description>Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
          </group>
          <group group_id="O4">
            <title>1.5g Ginger</title>
            <description>Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Average Nausea Severity</title>
          <description>Nausea evaluated on a 7-point semantic rating scale anchored by &quot;1&quot; = &quot;Not at all nauseated&quot; and by &quot;7&quot; = &quot;Extremely nauseated.&quot; Acute nausea calculated as the average of the Day 1 Evening and Night nausea ratings.
Change from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of average acute nausea used as the outcome measure.
Negative values for this outcome are favorable.</description>
          <population>Eligible patients 18 years of age or older, able to understand English, diagnosed with cancer, may have received more than one chemotherapy cycle and scheduled for at least three additional cycles; randomization stratified by CCOP site. A computer-generated random numbers table assigned patients to one of four treatment arms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.58"/>
                    <measurement group_id="O2" value="-0.44" spread="1.67"/>
                    <measurement group_id="O3" value="-0.34" spread="1.64"/>
                    <measurement group_id="O4" value="-0.05" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Mean difference between 0.5g and placebo of change from baseline of Average Acute Nausea = 0.
Ha: Mean difference between 0.5g and placebo of change from baseline of Average Acute Nausea &gt; 0. (Two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>The p-value was adjusted using theTukey-Kramer method</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model analyses and Type 3 tests of fixed effects using the Kenward-Roger degrees of freedom procedure were used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.441</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.127</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter (mean difference) is the difference in mean change from baseline (post-intervention - baseline) between groups (0.5 gm ginger - placebo). Negative values are favorable for the ginger group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: Mean difference between 1.0g and placebo of change from baseline of Average Acute Nausea = 0.
Ha: Mean difference between 1.0g and placebo of change from baseline of Average Acute Nausea &gt; 0. (Two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <p_value_desc>The p-value was adjusted using theTukey-Kramer method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model analyses and Type 3 tests of fixed effects using the Kenward-Roger degrees of freedom procedure were used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.402</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.124</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter (mean difference) is the difference in mean change from baseline (post-intervention - baseline) between groups (1 gm ginger - placebo). Negative values are favorable for the ginger group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>H0: Mean difference between 1.5g and placebo of change from baseline of Average Acute Nausea = 0.
Ha: Mean difference between 1.5g and placebo of change from baseline of Average Acute Nausea &gt; 0. (Two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.738</p_value>
            <p_value_desc>The p-value was adjusted using theTukey-Kramer method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model analyses and Type 3 tests of fixed effects using the Kenward-Roger degrees of freedom procedure were used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.158</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.120</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter (mean difference) is the difference in mean change from baseline (post-intervention - baseline) between groups (1.5 gm ginger - placebo). Negative values are favorable for the ginger group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo vs Any Ginger. H0: Mean difference between [(0.5g +1.0g +1.5g) / 3] and placebo of change from baseline of Average Acute Nausea = 0.
Ha: Mean difference between [(0.5g +1.0g +1.5g) / 3] and placebo of change from baseline of Average Acute Nausea &gt; 0. (Two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Contrasts used for estimation.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.350</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.140</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter (mean difference) is the difference in mean change from baseline (post-intervention - baseline) between groups (any ginger - placebo). Negative values are favorable for the ginger group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
placebo: Given orally</description>
        </group>
        <group group_id="E2">
          <title>0.5g Ginger</title>
          <description>Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="E3">
          <title>1.0g Ginger</title>
          <description>Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="E4">
          <title>1.5g Ginger</title>
          <description>Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
ginger extract: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Blood disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness, dizziness, fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising/flushing, rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two main weaknesses of the study, which should be controlled for in future studies, were not controlling for chemotherapy regimens (i.e., high versus low emetogenic regimens) or the severity level of nausea before enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Charles E. Heckler, PhD, MS. Research Assistant Professor</name_or_title>
      <organization>University of Rochester Medical Center</organization>
      <phone>585-273-1141</phone>
      <email>checkler@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

